CBD Life Sciences Inc. (CBDL) Announces CBG Emerges as a Promising Focus in
Cancer Research Initiatives
https://www.otcmarkets.com/news-otcapi/news/d...d?id=89467
With the global cannabinoid market projected to surpass $50+ billion in the coming years and segments like minor cannabinoids expected to grow at double-digit CAGR, cannabigerol (CBG) is rapidly emerging as a high-growth frontier—drawing attention for its non-psychoactive profile and early-stage research highlighting potential roles in oncology pathways and treatment support.
SCOTTSDALE, AZ / March 24, 2026 / — CBD Life Sciences Inc. (OTC: CBDL), an emerging leader in cannabinoid innovation and high-growth wellness markets, today announced a major expansion of its CBG-focused product program, strategically positioning the Company at the forefront of one of the most promising segments in the evolving cannabinoid landscape.
The expansion includes the launch of CBG-infused vape cartridges, tinctures, and advanced pain relief creams, as CBDL aligns with accelerating scientific interest and consumer demand surrounding cannabigerol (CBG).
CBG: A Next-Generation Cannabinoid Gaining Scientific Traction
While the U.S. Food and Drug Administration (FDA) has not approved CBG as a treatment for cancer, a growing body of preclinical research is driving increased attention from both the scientific community and investors.
Studies published through respected research institutions, including the National Institutes of Health (NIH) and PubMed Central (PMC), suggest that CBG may influence cancer-related biological pathways through several mechanisms:
[list]
[*]Inducing apoptosis (programmed cell death) in cancer cells, including colorectal carcinoma, glioblastoma, and leukemia
[*]Disrupting tumor growth cycles through cell cycle arrest
[*]Interacting with key receptors such as TRPM8 and PPARγ, which are associated with tumor progression and suppression
[*]Targeting therapy-resistant cancer stem cells, particularly in aggressive cancers like glioblastoma
[/list]
These early findings are fueling increased global interest in CBG as a compound of significance in next-generation cannabinoid research.
Expanding Role in Supportive Care Markets
In addition to tumor-related research, CBG is being explored for its potential to support patients undergoing conventional treatments such as chemotherapy—an area representing a significant and growing market opportunity:
[list]
[*]Appetite stimulation without psychoactive effects
[*]Neuropathic pain relief, including chemotherapy-induced nerve damage
[*]Nausea modulation, with ongoing research into dosage optimization
[/list]
This dual potential—spanning both research-driven oncology interest and high-demand wellness applications—positions CBG as a uniquely valuable cannabinoid within the industry.
CBDL Expands Product Portfolio to Capture Demand
CBD Life Sciences is actively capitalizing on this momentum with a targeted rollout of premium CBG products designed for scalability, consumer adoption, and market differentiation:
[list]
[*]CBG Vape Cartridges – Fast-acting delivery for immediate absorption
[*]CBG Tinctures – Precise, versatile dosing for daily wellness routines
[*]CBG Pain Relief Creams – Advanced topical formulations targeting inflammation and localized discomfort
[/list]
This expansion reflects CBDL's commitment to innovation, product diversification, and capturing emerging high-margin categories within the cannabinoid sector.
Leadership Perspective: Positioning for Long-Term Growth
"CBG represents one of the most exciting opportunities we've seen in the cannabinoid space," said Lisa Nelson, President and Chief Executive Officer of CBD Life Sciences Inc. "As research continues to uncover its potential, we are moving aggressively to position CBDL at the center of this emerging market. Our focus is on building a strong product ecosystem around CBG while delivering long-term value to our shareholders."
Strategic Alignment with a High-Growth Industry
As the cannabinoid market continues its rapid expansion, CBG is quickly emerging as a key differentiator for forward-thinking companies. Its non-psychoactive nature, combined with increasing scientific attention and consumer awareness, is driving a new wave of demand across both retail and research-driven segments.
CBDL believes its early entry and focused investment in CBG product development positions the Company to:
[list]
[*]Capture first-mover advantage in an emerging cannabinoid category
[*]Expand market share across multiple product verticals
[*]Strengthen brand authority in next-generation cannabinoid innovation
[*]Drive long-term revenue growth and shareholder value
[/list]
Cancer Research Initiatives
https://www.otcmarkets.com/news-otcapi/news/d...d?id=89467
With the global cannabinoid market projected to surpass $50+ billion in the coming years and segments like minor cannabinoids expected to grow at double-digit CAGR, cannabigerol (CBG) is rapidly emerging as a high-growth frontier—drawing attention for its non-psychoactive profile and early-stage research highlighting potential roles in oncology pathways and treatment support.
SCOTTSDALE, AZ / March 24, 2026 / — CBD Life Sciences Inc. (OTC: CBDL), an emerging leader in cannabinoid innovation and high-growth wellness markets, today announced a major expansion of its CBG-focused product program, strategically positioning the Company at the forefront of one of the most promising segments in the evolving cannabinoid landscape.
The expansion includes the launch of CBG-infused vape cartridges, tinctures, and advanced pain relief creams, as CBDL aligns with accelerating scientific interest and consumer demand surrounding cannabigerol (CBG).
CBG: A Next-Generation Cannabinoid Gaining Scientific Traction
While the U.S. Food and Drug Administration (FDA) has not approved CBG as a treatment for cancer, a growing body of preclinical research is driving increased attention from both the scientific community and investors.
Studies published through respected research institutions, including the National Institutes of Health (NIH) and PubMed Central (PMC), suggest that CBG may influence cancer-related biological pathways through several mechanisms:
[list]
[*]Inducing apoptosis (programmed cell death) in cancer cells, including colorectal carcinoma, glioblastoma, and leukemia
[*]Disrupting tumor growth cycles through cell cycle arrest
[*]Interacting with key receptors such as TRPM8 and PPARγ, which are associated with tumor progression and suppression
[*]Targeting therapy-resistant cancer stem cells, particularly in aggressive cancers like glioblastoma
[/list]
These early findings are fueling increased global interest in CBG as a compound of significance in next-generation cannabinoid research.
Expanding Role in Supportive Care Markets
In addition to tumor-related research, CBG is being explored for its potential to support patients undergoing conventional treatments such as chemotherapy—an area representing a significant and growing market opportunity:
[list]
[*]Appetite stimulation without psychoactive effects
[*]Neuropathic pain relief, including chemotherapy-induced nerve damage
[*]Nausea modulation, with ongoing research into dosage optimization
[/list]
This dual potential—spanning both research-driven oncology interest and high-demand wellness applications—positions CBG as a uniquely valuable cannabinoid within the industry.
CBDL Expands Product Portfolio to Capture Demand
CBD Life Sciences is actively capitalizing on this momentum with a targeted rollout of premium CBG products designed for scalability, consumer adoption, and market differentiation:
[list]
[*]CBG Vape Cartridges – Fast-acting delivery for immediate absorption
[*]CBG Tinctures – Precise, versatile dosing for daily wellness routines
[*]CBG Pain Relief Creams – Advanced topical formulations targeting inflammation and localized discomfort
[/list]
This expansion reflects CBDL's commitment to innovation, product diversification, and capturing emerging high-margin categories within the cannabinoid sector.
Leadership Perspective: Positioning for Long-Term Growth
"CBG represents one of the most exciting opportunities we've seen in the cannabinoid space," said Lisa Nelson, President and Chief Executive Officer of CBD Life Sciences Inc. "As research continues to uncover its potential, we are moving aggressively to position CBDL at the center of this emerging market. Our focus is on building a strong product ecosystem around CBG while delivering long-term value to our shareholders."
Strategic Alignment with a High-Growth Industry
As the cannabinoid market continues its rapid expansion, CBG is quickly emerging as a key differentiator for forward-thinking companies. Its non-psychoactive nature, combined with increasing scientific attention and consumer awareness, is driving a new wave of demand across both retail and research-driven segments.
CBDL believes its early entry and focused investment in CBG product development positions the Company to:
[list]
[*]Capture first-mover advantage in an emerging cannabinoid category
[*]Expand market share across multiple product verticals
[*]Strengthen brand authority in next-generation cannabinoid innovation
[*]Drive long-term revenue growth and shareholder value
[/list]
